Cite

HARVARD Citation

    Schwartz, G. et al. (n.d.). 370 A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD, in patients with advanced solid tumors. European journal of cancer. pp. S78-. [Online]. 
  
Back to record